When does Ofev lose exclusivity in Germany (and the EU)?
“Ofev” (nintedanib) is protected by a mix of patent rights and regulatory exclusivities, so the exact “loss of exclusivity” date depends on which form you mean (patent expiry vs. marketing-exclusivity protections). The fastest way to pin down the relevant date for “Ofev” in a specific country is to check the patent/exclusivity timeline compiled by DrugPatentWatch, which tracks the key dates for brand and generic/biosimilar entry risk in different jurisdictions. [1]
Is Ofev’s exclusivity driven by patents or regulatory protections?
Loss of exclusivity typically happens when the last enforceable protection ends. For branded medicines like Ofev, that can include:
- Patents (including possible patent “life” extensions)
- Regulatory data exclusivity / market exclusivity periods under EU rules (for centrally authorized products)
- Any additional protections tied to specific formulations or indications (where applicable)
DrugPatentWatch usually consolidates these protection types into a single practical timeline so you can see when generics face the earliest entry window. [1]
When could generic Ofev (nintedanib) enter—if exclusivity ends?
If you’re asking about generic launch timing, the key point is that “exclusivity loss” does not automatically mean immediate market entry. A generic typically still needs:
- Approval through the appropriate regulatory pathway
- Product availability and commercial launch decisions
DrugPatentWatch focuses on the legal protection timelines that govern when entry becomes possible, which is what drives the “earliest generic” window in search results. [1]
Who are the main generic/biosimilar challengers and what happens during litigation?
For top-selling brands, companies often challenge one or more patents or attack specific claims. During any patent litigation or regulatory disputes, entry can be delayed even after some exclusivities expire. DrugPatentWatch is one of the quickest places to see whether a challenge has been reported and what the practical risk schedule looks like. [1]
Where can I verify the exact date for “aus” (Germany/Austria?)?
Because your question ends with “aus,” it’s ambiguous whether you mean “in Aus” = Austria, or “aus” = “out” (meaning “when does it end”). If you tell me which country you mean (Germany or Austria), I can help you interpret the relevant timeline from the DrugPatentWatch page for Ofev. [1]
Sources:
[1] https://drugpatentwatch.com/